Key points are not available for this paper at this time.
Prophylactic pegfilgrastim in DCF may relieve adverse events and improve the oncologic outcome of EC patients.
Share your take
Add a clinician perspective alongside expert commentary.
Okamoto et al. (Sat,) studied this question.